4-Methyl-3-nitro-benzoic acid, a migration inhibitor, prevents breast cancer metastasis in SCID mice

Cancer Lett. 2011 Jun 1;305(1):69-75. doi: 10.1016/j.canlet.2011.02.028. Epub 2011 Mar 22.

Abstract

Metastasis remains a formidable problem in malignant tumors. In this study, MTT assay revealed that 4-methyl-3-nitro-benzoic acid (MNBA) had no effect on cell viability and did not interfere with cell cycle in any breast cancer cell lines tested. However, treatment with MNBA on breast cancer cells can inhibit EGF-induced migration and chemotaxis in vitro. In vivo assay demonstrated that MNBA and Paclitaxel synergistically inhibited tumor growth and metastasis in breast cancer SCID mice xenografts. These results suggest that MNBA is a potent inhibitor cancer cell chemotaxis and may be developed into a novel anti-metastasis drug.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Blotting, Western
  • Breast Neoplasms / pathology*
  • Cell Line, Tumor
  • Cell Movement / drug effects*
  • Cell Separation
  • Female
  • Flow Cytometry
  • Humans
  • Mice
  • Mice, SCID
  • Neoplasm Metastasis / prevention & control
  • Nitrobenzoates / pharmacology*
  • Paclitaxel / pharmacology
  • Xenograft Model Antitumor Assays

Substances

  • 4-methyl-3-nitrobenzoic acid
  • Antineoplastic Agents
  • Nitrobenzoates
  • Paclitaxel